Get the Stockscreener App
3.26
5.51%
-0.19
After Hours:
3.29
0.03
+0.92%
Trisalus Life Sciences Inc stock is traded at $3.26, with a volume of 393.21K.
It is down -5.51% in the last 24 hours and down -29.13% over the past month.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
See More
Previous Close:
$3.45
Open:
$3.46
24h Volume:
393.21K
Relative Volume:
1.08
Market Cap:
$200.22M
Revenue:
$45.15M
Net Income/Loss:
$-39.23M
P/E Ratio:
-1.7824
EPS:
-1.829
Net Cash Flow:
$-18.93M
1W Performance:
+21.64%
1M Performance:
-29.13%
6M Performance:
-35.70%
1Y Performance:
-39.07%
1-Day Range:
$3.25
$3.508
1-Week Range:
$2.64
$3.5886
52-Week Range:
$2.20
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
3.26 | 211.89M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Investors to Inquire about Securities Investigation - ACCESS Newswire
TLSI Q1 2026 Earnings: EPS Surprises Positively Despite No Revenue, Stock DeclinesGlobal Trading Community - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life - The National Law Review
TriSalus Life Sciences (TLSI) Q1 2026 Earnings: EPS Surges Past Expectations, Yet Stock SlipsEBITDA Margin Trends - Newser
TLSI (TLSI) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Certain Stock Options of TriSalus Life Sciences, Inc. are subject to a Lock-Up Agreement Ending on 22-MAY-2026. - marketscreener.com
Certain Restricted Stock Units of TriSalus Life Sciences, Inc. are subject to a Lock-Up Agreement Ending on 22-MAY-2026. - marketscreener.com
James Pallotta reports 5.2% stake in TriSalus Life Sciences (TLSI) - Stock Titan
38 startups join Innosphere life-sciences incubator - BizWest
Levi & Korsinsky Announces Investigation of Securities Claims Against TLSI (TLSI) - GlobeNewswire
TriSalus (TLSI) CCO reports 543-share tax-withholding sale, retains over 125K shares - Stock Titan
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud - Business Wire
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
TriSalus Life Sciences, Inc. Common Stock (TLSI) Stock Price Today & Analysis - Gotrade
TLSI Insider Buying Surge: 5 Executives Purchase $1.3M in Stock - Meyka
TriSalus Life Sciences Director Purchased Shares Worth Over $1.5M - TradingView
TriSalus Life Sciences (TLSI) director buys 10,000 shares in open market - Stock Titan
Director Mats Wahlstrom boosts TriSalus (TLSI) stake with 60,000-share open-market buy - Stock Titan
TriSalus (TLSI) director and LLC add 610K shares in open-market buys - Stock Titan
TriSalus (TLSI) CEO Mary Szela adds 39,682 shares in open-market stock purchase - Stock Titan
TriSalus (TLSI) CFO adds 7,100 shares in open-market purchase - Stock Titan
Earnings call transcript: TriSalus Life Sciences Q1 2026 sees stock gain despite revenue dip By Investing.com - Investing.com Australia
Earnings call transcript: TriSalus Life Sciences Q1 2026 sees stock gain despite revenue dip - Investing.com UK
TLSI SHAREHOLDER INVESTIGATION: SueWallSt Investigates TLSI for Possible Securities Law Violations - PR Newswire
TriSalus Life Sciences Q1 earnings call highlights - MSN
TLSI Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of TLSI (TLSI) - Morningstar
TriSalus Stockholders Back Directors, Auditor and Pay Policies - The Globe and Mail
First Light, Mathew P. Arens disclose 5.37M TLSI shares (TLSI) - Stock Titan
TriSalus (TLSI) grants RSUs and stock options to director Kerry Hicks - Stock Titan
TriSalus (TLSI) director granted RSU and stock option awards - Stock Titan
TriSalus (TLSI) director receives RSU and stock option grants - Stock Titan
TriSalus (TLSI) director Matlin receives RSU and option grants for 2026 service - Stock Titan
TriSalus Life Sciences (TLSI) director granted RSUs and stock options in 2026 award - Stock Titan
TriSalus Life Sciences (TLSI) directors re-elected and pay plan backed in 2026 vote - Stock Titan
TriSalus (TLSI) Q1 2026 Earnings Transcript - AOL.com
Canaccord Genuity Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI) - The Globe and Mail
Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results - Sahm
Dow Falls 200 Points; US Producer Prices Surge In April - Sahm
CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Lake Street Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
JonesTrading Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
TriSalus Life Sciences Bets Big Amid FDA Delay - TipRanks
TriSalus Life Sciences, Inc. Stock 12‑Month Price Target Cut to $8.8, Implies 93% Upside - TradingView
Earnings call transcript: TriSalus Life Sciences Q1 2026 revenue dips amid expansion By Investing.com - Investing.com India
TriSalus Life Sciences, Inc. (TLSI) reports Q1 loss, lags revenue estimates - MSN
TriSalus Life Sciences Q1 Earnings Call Highlights - sharewise.com
TriSalus Life Sciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
TLSI: Landmark PEDD study and expanded sales force set stage for growth despite revised 2026 guidance - TradingView
TLSI: Landmark PEDD study and commercial expansion drive revised 2026 outlook and growth strategy - TradingView
TriSalus Life Sciences Q1 2026 Earnings Call: Complete Transcript - Benzinga
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):